LMAT Form 4: Director Sells 976 Shares at $92.78

LeMaitre Vascular insider sale disclosed on Form 4.

Rhea-AI Filing Summary

LeMaitre Vascular insider sale disclosed on Form 4. Director Lawrence J. Jasinski sold 976 shares of Common Stock on 08/12/2025 at $92.78 per share, and after the transaction beneficially owned 4,773 shares directly. The filing lists the issuer as LeMaitre Vascular, Inc. (LMAT) and indicates the Form 4 was filed as an individual report. The document contains no options or other derivative transactions.

Positive

• None.

Negative

• Director Lawrence J. Jasinski reported a sale of 976 shares of LeMaitre Vascular common stock on 08/12/2025 at $92.78 per share.

Insights

Securities Analyst

TL;DR: A routine insider sale by a director; limited standalone market implication without further context.

The Form 4 shows a single non-derivative transaction: 976 shares sold at $92.78 on 08/12/2025, leaving the director with 4,773 shares. As presented, this is a straightforward disclosure of a sale by a director and does not include accompanying derivative activity or an indication of a Rule 10b5-1 plan. Without additional filings or context about the director's historical trading patterns or the size of the holding relative to total outstanding shares, the sale should be treated as an informational corporate insider activity rather than definitive evidence of company-wide developments.

Corporate Governance Expert

TL;DR: Compliance filing meeting Section 16 disclosure requirements; no governance red flags visible in this record.

The disclosure identifies the reporting person as a director and records a direct sale of common stock. The Form 4 entries are complete for non-derivative holdings and show no indirect beneficial ownership or additional transactions. The presence of a signature block and filing dates indicates procedural compliance. There is no evidence in this filing of unusual trading patterns, pledging, or derivative use that would raise immediate governance concerns.

Insider Trade Summary

Net Seller: 976 shares

Net Sell 1 txn

Insider Jasinski Lawrence J

Role Director

Sold 976 shs ($91K)

Type	Security	Shares	Price	Value
Sale	Common Stock	976	$92.78	$91K

Holdings After Transaction: Common Stock — 4,773 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 4 filed for LMAT disclose?

The Form 4 discloses that director Lawrence J. Jasinski sold 976 shares of LeMaitre Vascular common stock on 08/12/2025 at $92.78 per share and now beneficially owns 4,773 shares.

What is the reporting person's relationship to LMAT?

The reporting person, Lawrence J. Jasinski, is identified as a Director of LeMaitre Vascular, Inc.

Were any derivative securities reported in this Form 4 for LMAT?

No. The filing contains entries only in Table I for non-derivative common stock and shows no derivative transactions in Table II.

How many shares does the director own after the reported transaction?

Following the reported sale, the director beneficially owns 4,773 shares of common stock.

When was the transaction executed and when was the Form 4 filed?

The transaction date is 08/12/2025. The signature on the form is dated 08/14/2025, indicating the filing was made around that time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jasinski Lawrence J

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		976	D	$92.78	4,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nathan Ulrich	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.